Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.77 USD
-0.17 (-4.31%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Brokerage Reports
Aldeyra Therapeutics, Inc. [ALDX]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Reproxalap Clarity Defines DED Path Forward-Reinstating Buy Rating and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Broadening RASP Platform During 2024-Reproxalap Next Clinical Steps Forthcoming; Reit Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Positive Phase 2 ADX-629 Topline Supports RASP Modulation; Looking to Next Gen Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Reproxalap CRL Can Benefit From SPA Alignment; Feedback Expected December 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
November to Bring Clarity For Possible Reproxalap Partnership, Approval, or Delay
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Announced AbbVie Option Agreement-Validating Support With Remaining Questions
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Update From FDA Minutes Presents Reproxalap Uncertainty; Rating Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
ADX-2191 Traction in RP Exemplifies Upside, Building on Reproxalap; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
ADX-2191 As Pipeline Upside, Distinct From RASP Modulatory Progress; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
RASP Validation Sets Positive Stage for Reproxalap PDUFA in DED; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
2023-A Catalyst-Driven Year for the Pipeline, Prospective Approvals; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Catalyst-Rich 2023 With Broader RASP Modulatory Platform Reach; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Announced 12-Month Safety Supportive of Reproxalap in DED; Looking to November 2023 PDUFA; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Positive RASP Modulation Support From ADX-629-Several Coals in the Fire
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Reproxalap, RASP Modulation and ADX-2191-Near-Term Catalyst Focus; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
ADX-2191 Asserts Pipeline Diversity Beyond RASP Modulation Focus
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Turning New Page in Dry Eye Disease-Reproxalap NDA Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Dry Eye Disease Crossover Trial Solidifies Reproxalap Path to NDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Reproxalap Delivers in TRANQUILITY-2 Trial; Looking Next to Type B Pre-NDA Meeting 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Aldeyra Therapeutics, Inc.
Industry: Medical - Drugs
Focusing on Reproxalap TRANQUILITY-2 Results Expected 2Q22; With RASP Inhibitor Platform Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M